
White Paper:
4 Things You Need to Know About Combination Drug Compliance

Some of the key factors driving this growth include: higher levels of patient compliance, demand for minimally invasive surgeries, opportunities for precise pain relief, quicker healing and governments and non-governmental organizations (NGO) embracing combination drugs for their ease of administration.
Combination products defined in 21 CFR 3.2(e)2 are therapeutic and diagnostic products that are composed of any combination of a drug, device, or biological products, with the intention of creating safer, more effective, precisely targeted and easier to administrate therapies.
While the technologies and innovations driving the combination product market deliver a great deal of value to patients and to the medical community, the novelty of these products is often challenging for drug developers and regulatory agencies. The marriage of two different disciplines – drug and medical device – creates a complex regulatory process that must be well managed. In addition, evolving regulations as the combination product segment matures can present challenges for older, legacy combination products.
SEE ALSO: The Formation of the Combination Products Policy Council to Improve Regulatory Efficiency
Download the Whitepaper
Complete the form below to download your copy!
You might also be interested in…
Navigating the European Union’s (EU) Drug Device Combination Product Regulatory Changes
White Paper: Navigating the European Union’s (EU) Drug Device Combination Product Regulatory ChangesThe European therapeutics market has been working to manage the upheaval caused by Brexit and is now working its way through yet another challenge: the medical devices...
Process Validation for Expedited Approval Drugs
White Paper: Process Validation and Regulatory Review in the Age of Expedited Approval Drugs Expedited approval drugs have profoundly changed the thinking and approach to Process Validation and other CMC activities. When working on the development of an expedited...
Cell Therapies – Overcoming Challenges Within the Regulatory Framework
White Paper: Cell Therapies Come of Age: Overcoming Challenges Within the Regulatory FrameworkWithin the cell therapy arena, regulators, the medical community and industry alike are often confronted with an unsettling question. What is this, really? Should a given...